当地时间3月29日至31日，第74届美国心脏病学会科学年会（ACC.25）即将在美国芝加哥盛大召开。本届年会共设置了6个最新突破性临床试验（Late-Breaking Clinical Trials，LBCTS）专场、5个特色临床研究（Featured Clinical Research，FCR）专场、2个临床和研究视野（Clinical and Investigative Horizons）和2个最新突破性临床试验深入探究（Late-Breaking Clinical Trial Deep Dive）专场等多场精彩会议。其中，LBCTS专场即将公布23项最新突破性临床试验成果，本文带您先睹为快！

作者：Xuemei Guo

一、Late-Breaking Clinical Trials I (Session 102)

北京时间：3月29日，22:30-23:30

当地时间：Saturday, March 29, 9:30-10:30 a.m. CT

会议地点：Main Tent, North Hall B

1）Primary and Secondary Outcomes of the Women's Ischemia Trial to Reduce Events in Non-Obstructive Coronary Artery Disease

女性缺血试验的主要和次要结局：在女性非阻塞性冠脉疾病患者中探究事件风险的降低

讲者：Carl Pepine

2）The Effect of Once-weekly Subcutaneous Semaglutide on Functional Capacity in People With Type 2 Diabetes and Peripheral Artery Disease: Primary Results From the Phase 3b, Randomized, Placebo-Controlled, Double Blind Stride Trial

STRIDE 3b期随机、双盲、安慰剂对照试验的主要结果：每周皮下注射一次司美格鲁肽对2型糖尿病合并外周动脉疾病患者功能能力的影响

讲者：Marc Bonaca

3）Extended Anticoagulant Treatment With a Reduced Versus Full Dose Apixaban in Patients With Cancer-Associated Venous Thromboembolism: The API-CAT Study

API-CAT试验：癌症相关静脉血栓栓塞患者使用减量与全剂量阿哌沙班进行延长抗凝治疗的疗效

讲者：Isabelle MAHE

二、Late-Breaking Clinical Trials II (Session 104)

北京时间：3月30日，02:30-03:30

当地时间：Saturday, March 29, 1:30-2:30 p.m. CT

会议地点：Main Tent, North Hall B

1）Oral Semaglutide Reduces Cardiovascular Events in People With Type 2 Diabetes With Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

SOUL随机试验的主要结果：口服司美格鲁肽对合并动脉粥样硬化性心血管疾病和/或慢性肾脏病的2型糖尿病患者心血管事件的影响

讲者：Darren McGuire

2）Efficacy of Lorundrostat, A Novel Aldosterone Synthase Inhibitor, In Patients With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

在标准降压药物治疗的基础上，新型醛固酮合酶抑制剂Lorundrostat治疗血压控制不佳患者的疗效

讲者：Luke Laffin

3）Development and External Validation of a Deep Learning Electrocardiogram Model For Risk Stratification of Coronary Revascularization Need in the Emergency Department

在急诊科用于冠脉血运重建风险分层的深度学习心电图模型的开发与外部验证

讲者：Antonius Buescher

4）Dapagliflozin in Patients Undergoing Transcatheter Aortic Valve Implantation

在经导管主动脉瓣植入术后患者中进行达格列净治疗的疗效

讲者：Sergio Raposeiras Roubin

三、Late-Breaking Clinical Trials III (Session 105)

北京时间：3月30日，04:00-05:00

当地时间：Saturday, March 29, 3-4 p.m. CT

会议地点：Main Tent, North Hall B

1）Efficacy of Rivaroxaban Versus Warfarin in Patients With Acute Left Ventricular Thrombus Following Myocardial Infarction: An Open-Label Randomized Controlled Trial RIVAWAR Trial Investigators

RIVAWAR开放标签随机对照试验：在心梗后急性左心室血栓患者中，比较利伐沙班和华法林的疗效

讲者：Jehangir Ali Shah

2）Four-Factor Prothrombin Complex Concentrate is Superior to Frozen Plasma in Bleeding Adult Cardiac Surgery Patients With Coagulopathy — Results From a Phase 3, Randomized, Active-Control Study

3期随机、阳性对照试验：在合并凝血功能障碍的成人心脏手术出血患者中，四因子凝血酶原复合物浓缩物的疗效优于冷冻血浆

讲者：Keyvan Karkouti

3）The Main Results of the Phase 3 Reverse-it Trial

REVERSE-IT 3期试验的主要结果

讲者：Deepak Bhatt

4）Stratified Randomization Study to Compare Different Duration of Dual Antiplatelet Therapy After Coronary Stenting in Either High or Low Bleeding Risk Population

在置入冠脉支架术后的高或低出血风险人群中，对比不同时长双联抗血小板治疗的分层随机试验

讲者：Hyo-Soo Kim

四、Late-Breaking Clinical Trials IV (Session 106)

北京时间：3月30日 21:00-22:00

当地时间：Sunday, March 30, 8-9 a.m. CT

会议地点：Main Tent, North Hall B

1）Comparative Effectiveness of Mobile Integrated Health Versus a Transitions of Care Coordinator in Patients With Heart Failure: Results From the MIGHTy-Heart Trial

MIGHTy-Heart试验结果：移动综合健康与护理协调员在心衰患者中的有效性比较

讲者：Ruth Masterson Creber

2）Liberal Fluid Intake Versus Fluid Restriction in Chronic Heart Failure

在慢性心力衰竭患者中，对比自由液体摄入与限制液体摄入的疗效

讲者：Roland Van Kimmenade

3）The Equiox Study: Evaluating Pulse Oximeter Bias Across a Range of Skin Pigment in Critically Ill Adults

EQUIOX试验：评估危重症成人不同肤色下脉搏血氧仪的偏差

讲者：Carolyn Hendrickson

4）Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF2) Trial

FAIR-HF2试验：评估羧麦芽糖铁对缺铁性贫血合并慢性心衰患者发病率和死亡率的影响

讲者：Stefan Anker

五、Late-Breaking Clinical Trials V (Session 107)

北京时间：3月30日 23:00-24:00

当地时间：Sunday, March 30, 10-11 a.m. CT

会议地点：Main Tent, North Hall B

1）Routine Cerebral Embolic Protection in Transcatheter Aortic Valve Implantation: The British Heart Foundation (BHF) PROTECT-TAVI Trial

英国心脏基金会（BHF）PROTECT-TAVI试验：经导管主动脉瓣植入术中常规脑栓塞保护的疗效

讲者：Rajesh Kharbanda

2）Clinical And Echocardiographic Outcomes Among the First 500 Patients Treated With a Dedicated Transcatheter Aortic Valve For Pure Aortic Regurgitation in the Align-AR Clinical Trial

Align-AR临床试验中首次采用专用经导管主动脉瓣治疗单纯主动脉瓣反流的500例患者的临床和超声心动图结果

讲者：Raj Makkar

3）5-year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis

低危主动脉瓣狭窄患者进行经导管或外科主动脉瓣置换术后的5年结局比较

讲者：Michael Reardon

4）Comparison of Angiography-Derived Fractional Flow Reserve-Guided and Intravascular Ultrasound-Guided Percutaneous Coronary Intervention Strategies: The FLAVOUR II Trial

FLAVOUR II试验：比较血管造影衍生的血流储备分数指导与血管内超声指导的经皮冠脉介入治疗的疗效

讲者：浙江大学医学院附属第二医院  王建安

六、Late-Breaking Clinical Trials VI (Session 108)

北京时间：3月31日 00:30-01:30

当地时间：Sunday, March 30, 11:30 a.m.-12:30 p.m. CT

会议地点：Main Tent, North Hall B

1）Two-Year Outcomes of Transcatheter Tricuspid Valve Edge-to-Edge Repair For Tricuspid Regurgitation: The Triluminate Pivotal Trial

Triluminate关键试验：经导管三尖瓣缘对缘修复治疗三尖瓣反流的2年结局

讲者：Saibal Kar

2）Fractional Flow Reserve Guided Percutaneous Coronary Intervention Compared With Bypass Surgery: Final 5 Year Results of the Fractional Flow Reserve Versus Angiography For Multivessel Evaluation 3 Trial

多支病变FFR vs. 造影评估3期试验的5年最终结果：FFR指导的经皮冠脉介入治疗 vs冠状动脉搭桥的疗效

讲者：William Fearon

3）Clopidogrel Versus Aspirin For Long-Term Maintenance Monotherapy in Patients With High Ischemic Risk After Percutaneous Coronary Intervention

在进行经皮冠脉介入治疗的高缺血风险患者中，应用氯吡格雷或阿司匹林进行长期单药维持治疗的疗效对比

讲者：Joo-Yong Hahn

4）Alliance For Secondary Prevention After an Acute Coronary Syndrome

急性冠脉综合征二级预防联合治疗

讲者：Giulia Magnani